Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase® G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase® G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use level.

Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97 / Panel on Dietetic Products, Efsa; Allergies, Nutrition and; Turck, Dominique; Bresson, Jean Louis; Burlingame, Barbara; Dean, Tara; Fairweather Tait, Susan; Heinonen, Marina; Hirsch Ernst, Karen Ildico; Mangelsdorf, Inge; Mcardle, Harry J.; Naska, Androniki; Neuh€auser Berthold, Monika; Nowicka, Gra_zyna; Pentieva, Kristina; Sanz, Yolanda; Siani, Alfonso; Sj€odin, Anders; Stern, Martin; Tome, Daniel; Vinceti, Marco; Willatts, Peter; Engel, Karl Heinz; Marchelli, Rosangela; P€oting, Annette; Poulsen, Morten; Schlatter, Josef; Gelbmann, Wolfgang; Loveren, Henk Van. - In: EFSA JOURNAL. - ISSN 1831-4732. - 15:2(2017), pp. 4681-4681. [10.2903/j.efsa.2017.4681]

Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97

VINCETI, Marco;
2017

Abstract

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase® G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase® G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use level.
2017
15
2
4681
4681
Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97 / Panel on Dietetic Products, Efsa; Allergies, Nutrition and; Turck, Dominique; Bresson, Jean Louis; Burlingame, Barbara; Dean, Tara; Fairweather Tait, Susan; Heinonen, Marina; Hirsch Ernst, Karen Ildico; Mangelsdorf, Inge; Mcardle, Harry J.; Naska, Androniki; Neuh€auser Berthold, Monika; Nowicka, Gra_zyna; Pentieva, Kristina; Sanz, Yolanda; Siani, Alfonso; Sj€odin, Anders; Stern, Martin; Tome, Daniel; Vinceti, Marco; Willatts, Peter; Engel, Karl Heinz; Marchelli, Rosangela; P€oting, Annette; Poulsen, Morten; Schlatter, Josef; Gelbmann, Wolfgang; Loveren, Henk Van. - In: EFSA JOURNAL. - ISSN 1831-4732. - 15:2(2017), pp. 4681-4681. [10.2903/j.efsa.2017.4681]
Panel on Dietetic Products, Efsa; Allergies, Nutrition and; Turck, Dominique; Bresson, Jean Louis; Burlingame, Barbara; Dean, Tara; Fairweather Tait, Susan; Heinonen, Marina; Hirsch Ernst, Karen Ildico; Mangelsdorf, Inge; Mcardle, Harry J.; Naska, Androniki; Neuh€auser Berthold, Monika; Nowicka, Gra_zyna; Pentieva, Kristina; Sanz, Yolanda; Siani, Alfonso; Sj€odin, Anders; Stern, Martin; Tome, Daniel; Vinceti, Marco; Willatts, Peter; Engel, Karl Heinz; Marchelli, Rosangela; P€oting, Annette; Poulsen, Morten; Schlatter, Josef; Gelbmann, Wolfgang; Loveren, Henk Van
File in questo prodotto:
File Dimensione Formato  
j.efsa.2017.4681.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1133431
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact